Ignyta Inc. (RXDX) 9.92 $RXDX Ignyta Announces Multiple

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ignyta Inc. (RXDX) 9.92 $RXDX

Ignyta Announces Multiple Presentations at the 2015 AACR Annual Meeting
Business Wire - Sat Apr 18, 12:00PM CDT
Ignyta, Inc. (Nasdaq:RXDX), a precision oncology biotechnology company, today announced three poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2015 in Philadelphia, Pennsylvania.
RXDX: 9.92 (-0.30)

InsiderInsights.com Daily Round Up 3/24/15: FANG, GLP, CPTA, ANET
InsiderInsights - at Seeking Alpha - Wed Mar 25, 12:50PM CDT

EGLE: 8.55 (+0.05), ANET: 66.27 (+0.40), MMI: 37.17 (-0.02), BUI: 19.71 (+0.06), LLY: 72.30 (+0.09), HRZN: 14.11 (+0.03), K: 63.98 (+0.12), WIW: 11.45 (unch), CPTA: 17.65 (-0.07), GLP: 40.11 (+0.96), WD: 18.77 (+0.13), RXDX: 9.92 (-0.30), CVEO: 3.30 (-0.09), DYN: 33.28 (+0.24), FANG: 81.98 (-0.83), ZAYO: 27.24 (-0.08), BDJ: 8.28 (+0.07), ROST: 103.90 (+0.28), ALCO: 48.09 (-1.52), WIA: 11.60 (-0.04)

InsiderInsights.com Daily Round Up 3/18/15: DO, ASPS, CGIX, ADMA
InsiderInsights - at Seeking Alpha - Thu Mar 19, 11:55AM CDT

MPW: 14.71 (+0.03), SSNC: 63.47 (+0.76), SANW: 4.45 (-0.20), ADMA: 8.98 (-0.03), ASPS: 18.07 (+1.32), MMI: 37.17 (-0.02), PSA: 192.81 (+1.17), ENOC: 11.19 (+0.02), PCLN: 1,212.90 (+18.64), CGIX: 9.97 (-0.18), FDS: 158.49 (+0.26), GGP: 28.67 (-0.03), NEE: 103.29 (-0.11), DO: 30.07 (-0.02), RXDX: 9.92 (-0.30), DYN: 33.28 (+0.24), TCB: 15.41 (+0.16), TWTR: 51.73 (+0.41), RGS: 17.40 (+0.01)

Investors Relieved? Akorn Stock Retakes 50-Day Line
at Investor's Business Daily - Wed Mar 18, 2:45PM CDT
Akorn (AKRX) shares made big gains in the stock market today. The drugmaker had to restate its Q2 and Q3 2014 financial statements because of an error that led to an overstatement of revenue and earnings in Q2. But investors seem to be relieved by...
ESPR: 100.53 (-2.60), RXDX: 9.92 (-0.30), AKRX: 53.70 (-1.69), AMGN: 169.10 (+0.64), TEVA: 63.01 (-1.15), SNY: 51.59 (+0.03), NKTR: 10.90 (+0.16), REGN: 472.63 (+9.41)

Teva Sells Four Oncology Development Assets to Ignyta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 2:44PM CDT
Teva (TEVA) announced the sale of its worldwide rights and assets related to four targeted oncology development programs to Ignyta Inc. (RXDX), for 1.5 million shares of Ignyta???s stock.
RXDX: 9.92 (-0.30), AKRX: 53.70 (-1.69), TEVA: 63.01 (-1.15), ACOR: 33.34 (-1.33)

Ignyta incurs higher net loss of USD40.0m in 2014
M2 - Wed Mar 18, 6:04AM CDT
Oncology company Ignyta (Nasdaq:RXDX) disclosed on Tuesday that it recorded a net loss of USD40.0m (USD2.18 per share) for the full year ended 31 December 2014.
RXDX: 9.92 (-0.30)

Ignyta's (RXDX) CEO Jonathan Lim on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 7:50PM CDT

RXDX: 9.92 (-0.30)

Akorn Leads 5 Drug Stocks Moving After Hours On News
at Investor's Business Daily - Tue Mar 17, 7:10PM CDT
IBD's top two industries this week are Medical-Biotech/Biomed and Medical-Generic Drugs. Several companies from these top groups reported market-moving news after Tuesday's market close. Here are five: Akorn Restates, Stock Rises Akorn (AKRX) late...
ACT: 295.22 (+0.69), ESPR: 100.53 (-2.60), RXDX: 9.92 (-0.30), AKRX: 53.70 (-1.69), AMGN: 169.10 (+0.64), TEVA: 63.01 (-1.15), SNY: 51.59 (+0.03), NKTR: 10.90 (+0.16), REGN: 472.63 (+9.41)

Ignyta up 31% after hours on Teva oncology deal
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:37PM CDT

RXDX: 9.92 (-0.30), TEVA: 63.01 (-1.15)

Ignyta reports FY'14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:22PM CDT

RXDX: 9.92 (-0.30)

Ignyta Announces 2014 Full Year Company Highlights and Financial Results
Business Wire - Tue Mar 17, 3:15PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the full year ended December 31, 2014.
RXDX: 9.92 (-0.30)

Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva
Business Wire - Tue Mar 17, 3:00PM CDT
--Concurrent $42 million equity investment in Ignyta by Teva and selected healthcare investors
RXDX: 9.92 (-0.30), TEVA: 63.01 (-1.15)

Ignyta to Report 2014 Company Highlights and Financial Results and Host Conference Call and Webcast on March 17, 2015
Business Wire - Wed Mar 11, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it will release its 2014 financial results after the market closes on Tuesday, March 17, 2015. Ignyta management will host a conference call that same afternoon at 5:00 p.m. ET (2:00 p.m. PT) to provide company highlights, review the financial results and answer questions.
RXDX: 9.92 (-0.30)

Ignyta inks equity offering with Cantor Fitzgerald
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 7:07AM CST

RXDX: 9.92 (-0.30)

Ignyta's Lead Drug Gets Orphan Status for Colorectal Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 12:30PM CST
Ignyta, Inc. (RXDX) announced that the FDA has granted orphan drug designation to its lead candidate entrectinib for the treatment of ALK-positive colorectal cancer
LCI: 66.45 (-0.28), RXDX: 9.92 (-0.30), SLXP: 172.96 (+0.15), SCMP: 21.75 (+0.47)

Investing In Precision Oncology: Targeting NTRK Genomic Alterations
Bay Area Biotech - at Seeking Alpha - Wed Feb 18, 10:44AM CST

LOXO: 13.21 (-0.01), TSRO: 62.25 (-1.08), RXDX: 9.92 (-0.30), PFE: 34.93 (+0.04), MRTX: 27.86 (-0.19), NVS: 103.45 (-0.62), ARRY: 7.25 (-0.10)

Ignyta's lead product an Orphan Drug for colorectal cancer
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 6:22AM CST

RXDX: 9.92 (-0.30)

Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer
Business Wire - Tue Feb 17, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Ignyta's lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive or ALK-positive colorectal cancer.
RXDX: 9.92 (-0.30)

Ignyta's entrectinib an Orphan Drug for subset of NSCLC
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 7:46AM CST

RXDX: 9.92 (-0.30)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 32

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 89

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 73

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 40

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 129

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 18

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 192

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 62

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 74

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading

Top 5 Most Recently Viewed Articles

Legit Security Named as a Top Performer in Application Security

Updated Category News Views 210

Legit Security Recognized as a Leader in Application Security Legit Security, a leader in AI-native Application Security Posture Management (ASPM), has recently been acknowledged as a prominent player in the IDC MarketScape for ASPM. This achievement reflects the company's commitment to securing AI-powered application development processes. The IDC MarketScape report...

Continue Reading
Active Dental Transforms Patient Experience with New Website

Updated Category News Views 140

Active Dental Enhances Patient Accessibility with Unified Website Active Dental, a reputable family and general dentistry practice in the Dallas-Fort Worth metroplex, has launched a newly redesigned website that seamlessly integrates all five of its practice locations into a single, user-friendly digital platform. This significant upgrade aims to make appointment...

Continue Reading
Stork Club's Innovative Approach to Postpartum Depression Support

Updated Category News Views 229

Stork Club Innovates Reproductive Health Care Stork Club has recently launched an unprecedented initiative aimed at addressing postpartum depression (PPD) among working mothers. This pioneering program offers a seamless blend of digital diagnostics and therapy, leading to significant improvements in mental health outcomes. With up to 20% immediate relief from PPD symptoms...

Continue Reading
Investors Eye Class Action Against Fortrea Holdings, Inc.

Updated Category News Views 114

Understanding the Fortrea Holdings, Inc. Class Action Fortrea Holdings, Inc. (NASDAQ: FTRE) has gained attention due to rising investor concerns regarding its recent financial disclosures. Investors who have experienced losses over $100,000 are now presented with an opportunity to potentially lead a securities fraud lawsuit against the company. This lawsuit highlights...

Continue Reading
Alpha Tau Medical Plans Engagements at Key Healthcare Events

Updated Category News Views 91

Upcoming Participation in Major Healthcare Conferences Alpha Tau Medical Ltd., a leading developer of innovative cancer therapies, is gearing up for an exciting presence at significant healthcare conferences. The involvement of the Chief Financial Officer, Raphi Levy, at these events marks a pivotal opportunity for the company to showcase its groundbreaking...

Continue Reading